HCV E1 comprising specific disulfide bridges

Details HCV E1 comprising specific disulfide bridges HCV E1 comprising specific disulfide bridges

2005-03-08

2008-08-19

Lucas, Zachariah (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C435S069100, C435S069300, C424S184100, C424S189100, C424S192100, C424S204100

Reexamination Certificate

active

07413741

ABSTRACT:
The invention relates to recombinantly or synthetically produced HCV E1 envelope proteins or parts thereof comprising disulfides between specific cysteine residues. The invention further relates to viral-like particles and compositions comprising said HCV E1 envelope proteins or parts thereof as well as to methods using said HCV E1 envelope proteins or parts thereof, and to kits comprising said HCV E1 envelope proteins or parts thereof.

REFERENCES:
patent: 6635257 (2003-10-01), Depla
patent: 7101561 (2006-09-01), Maertens
patent: 2004/0126395 (2004-07-01), Maertens
patent: 2004/0185061 (2004-09-01), Bosman et al.
patent: WO 02/086101 (2002-10-01), None
patent: WO 99/67285 (1999-12-01), None
patent: WO 96/04301 (1996-02-01), None
patent: WO 98/50556 (1998-11-01), None
patent: WO 99/50301 (1999-10-01), None
patent: WO 02/085932 (2002-10-01), None
patent: WO 03/051912 (2003-06-01), None
Berzofsky et al., “Progress on new vaccine strategies against chronic viral infections,” The Journal of Clinical Investigation, vol. 114 No. 4, pp. 450-462 (Aug. 2004).
LeRoux-Roels, Development of prophylactic and therapeutic vaccines against hepatitis C virus, Expert Review of Vaccines, vol. 4 No. 3, pp. 351-371 (Jun. 2005).
Liang et al., “Pathogenesis, natural history, treatment, and prevention of hepatitis C,” Annals of Internal Medicine, vol. 132 No. 4, pp. 296-305 (Feb. 2000).
Rollier et al., “Control of Heterologous Hepatitis C Virus Infection in Chimpanzees Is Associated with the Quality of Vaccine-Induced Peripheral T-Helper Immune Response,” Journal of Virology, vol. 78 No. 1, pp. 187-196 (Jan. 2004).
Tan et al., “Strategies for hepatitis C therapeutic intervention: now and next ,”Current Opinion in Phamacology, vol. 4 No. 5, pp. 465-470 (Oct. 2004).
Lauer et al., “Vaccine-induced T-cell responses against HCV: one step taken, more to follow,” Gastroenterology, vol. 132 No. 4, pp. 1626-1628 (2007).
Merola et al. Folding of Hepatitis C Virus E1 Glycoprotein in a Cell Free System (2002) J Virol 75, 11205-11217.
Garry et al, Proteomics computational analyses suggest that hepatitis C virus E1 and pestivirus E2 envelope glycoproteins are truncated class II fusion proteins (2003) Virology 307, 255-265.
Partial European Search Report dated Aug. 27, 2004, issued in connection with EP 04 44 7057.
Sobolev et al, “Comparative analysis of amino acid sequences from envelope proteins isolated from different hepatitis C virus variants: possible role of conservative and variable regions”, J. Viral Hepatitis 7, pp. 368-374 (2000).
Deleersnyder et al, “Formation of Native Hepatitis C Virus Glycoprotein Complexes”, J. Virology 71, No. 1, pp. 697-704 (1997).
Hussy et al, “Purification and in vitro-phospholabeling of secretory envelope proteins E1 and E2 of hepatitis C Virus expressed in insect cells” Virus Research 45, pp. 45-57 (1996).

Affiliated with

Also associated with

Rating

HCV E1 comprising specific disulfide bridges does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HCV E1 comprising specific disulfide bridges, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HCV E1 comprising specific disulfide bridges will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4005906